ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 24 of 50
УЖМБС 2021, 6(1): 160–167
Clinical Medicine

The Platelet Automesoconcentrate in Patients with Orthopedical Pathology

Tsepkolenko V. O. 1, Pshenychnyi Т. Y. 2, Holiuk Ye. L. 2, Tymochuk V. V. 2, Derkach R. V. 2

The platelet automesoconcentrate is a complex biotechnological product based on autologous growth factors and oligopeptides obtained from the patient's blood platelets. The purpose of this study was evaluation of our own first treatment results and improvement of the quality of life in patients with pathology of the musculoskeletal system after treatment with platelet automesoconcentrate. Material and methods. We analyzed the results of 76 patients (24 patients with knee osteoarthritis, 21 patients with epicondylitis of the elbow joint and 31 patients with the knee joint meniscal lesions Stoller I-IIb), who were treated in the clinic of the State Institution "Institute of Traumatology and Orthopedics" of Academy of Medical Sciences of Ukraine and in the “Virtus” clinic. The quantitative and qualitative evaluation of pain was performed by visual analog scale score. The evaluation of dysfunction and quality of life were performed by the standardized Lysholm and Oxford scales according to the affected segment and pathology. Results and discussion. The positive dynamics of the knee joint functional ability was observed in cases of the 1 and 2 osteoarthrosis grades by 43.6% and 62.1% (in a year). In patients with osteoarthrosis grade 3, a slight improvement was observed in a short-term period, but after 6 months received results gradually decrease and after a year, they were only 4.3% compared with the baseline level (Oxford). The positive dynamics of the elbow joint functional ability for 3 months was 75%. In general, after 6 months, full recovery of the elbow joint function was observed in 15 patients, restrictions at high physical exertion remained in 6 patients. In case of the knee joint menisci lesion, an increase in functional activity was observed in 23 cases by more than 58.8% (Oxford) and increased mean values from 70 (before treatment) to 82 points (Lysholm). Conclusion. The study showed advantages of the platelets automesoconcentrate in patients with osteoarthrosis and the knee meniscal lesions, elbow joint epicondylitis, in clinically difficult cases with the ineffectiveness of previous treatment

Keywords: regenerative medicine, platelet automesoconcentrate, platelet-rich plasma

Full text: PDF (Ukr) 303K

  1. Wong VW, Wan DC, Gurtner GC, Longaker MT. Regenerative surgery: tissue engineering in general surgical practice. World journal of surgery. 2012; 36(10): 2288-2299.
  2. Marx RE. Platelet-Rich Plasma: Evidence to Support Its Use. Journal of Oral and Maxillofacial Surgery. 2004; 62(4): 489-96.
  3. Anitua E, Andia I, Bruno Ardanza B. Nurden P. Nurden A.T. Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost. 2004; 91(01): 4-15
  4. Mariani E, Pulsatelli L. Platelet Concentrates in Musculoskeletal Medicine. Int J Mol Sci. 2020 Feb; 21(4): 1328.
  5. Gentile P, Garcovich S. Systematic Review—The Potential Implications of Different Platelet-Rich Plasma (PRP) Concentrations in Regenerative Medicine for Tissue Repair. Int J Mol Sci. 2020 Aug; 21(16): 5702.
  6. Xie X, Zhang C, Tuan RS. Biology of platelet-rich plasma and its clinical application in cartilage repair. Arthritis Res Ther. 2014; 16(1): 204.
  7. Gabriela Fernandes, Shuying Yang. Application of platelet-rich plasma with stem cells in bone and periodontal tissue engineering. Bone Res. 2016; 4: 16036.
  8. Pifer MA, Maerz T, Baker KC, Anderson K. Matrix metalloproteinase content and activity in low-platelet, low-leukocyte and high-platelet, high-leukocyte platelet rich plasma (PRP) and the biologic response to PRP by human ligament fibroblasts. Am J Sports Med. 2014; 42(5): 1211–1218.
  9. Kobayashi Y, Saita Y, Nishio H, Ikeda H, Takazawa Y, Nagao M, et al. Leukocyte concentration and composition in platelet-rich plasma (PRP) influences the growth factor and protease concentrations. J Orthop Sci. 2016; 21(5): 683–689.
  10. Ott I, Neumann FJ, Gawaz M, Schmitt M, Schomig A. Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation J. 1996; 94: 1239–46.
  11. Mickelson JK, Lakkis NM, Villarreal-Levy G, Hughes BJ, Smith CW. Leukocyte activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent disease? J Am Coll Cardiol. 1996; 28: 345–53.
  12. Furman MI, Barnard MR, Krueger LA, Fox ML, Shilale EA, Lessard DM, et al. Circulating Monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol. 2001; 38: 1002–6.
  13. Htun P, Fateh-Moghadam S, Tomandl B, Klinger K, Stellos K, Garlichs C, et al. Course of platelet activation and platelet-leukocyte interaction in cerebrovascular ischemia. Stroke. 2006; 37: 2283–7.
  14. Finsterbusch M, Schrottmaier WC, Kral-Pointner JB, Salzmann M, Assinger A. Measuring and interpreting platelet-leukocyte aggregates. Platelets. 2018; 29(7): 677–685.
  15. Joseph JE, Harrison P, Mackie IJ, Isenberg DA. Increased circulating plateletleucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. Brithsh J Haematol. 2001; 115: 451–9.
  16. Singh MV, Davidson DC, Kiebala M, Maggirwar SB. Detection of circulating platelet-monocyte complexes in persons infected with human immunodeficiency virus type-1. J Virol Methods. 2012; 181 (2): 170–6.
  17. Maynard DM. Proteomic analysis of platelet alpha-granules using mass spectrometry. Journal of Thrombosis and Haemostasis. 2007; 5(9): 1945–1955.
  18. Lorenz HP, Longaker MT. Wounds: biology, pathology, and management. In book: Essential Practice of Surgery. Ed by J Norton. Springer; 2005.
  19. Blair P, Flaumenhaft R. Platelet